LABORATORY NEWS
-
Bostongene Recognized As Designated Laboratory For The ComboMATCH Precision Medicine Clinical Trial
BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
- STEMCELL Technologies Announces FDA De Novo Classification For Its EasySep CD138 Positive Selection Kit To Support Cancer Diagnostic Tests
- FormaPath Announces The Novel Tissue Biopsy Grossing Platform: nToto™
- Nucleus Genomics Launches To Bring Whole-Genome Sequencing To The Public
- Scientists Close In On TB Blood Test Which Could Detect Millions Of Silent Spreaders
ARCHIVED NEWSLETTER
- 03.26.24 -- Notable Public Comments On The FDA's Proposed Regulation For Laboratory Developed Tests
- 03.12.24 -- FDA's CBER Issues Final Guidance For CAR T Cell Products
- 02.27.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
- 02.13.24 -- FDA Issues Draft Guidance For Cell & Gene Therapy Potency Assurance
- 01.23.24 -- 4 Strategies To Formulate Poorly Soluble APIs
This website uses cookies to ensure you get the best experience on our website. Learn more